Adaptimmune Therapeutics plc (ADAP) has a consensus analyst rating of Buy, based on 16 analysts covering the stock. Of those, 9 recommend buying, 4 recommend holding, and 3 recommend selling.
The analyst consensus price target for ADAP is $2.83, representing a +5,735.1% upside from the current price of $0.0485. Price targets range from a low of $1.00 to a high of $4.00.
